US Stock MarketDetailed Quotes

IMRNW Immuron Limited C/Wts 12/05/2022 (To Pur Com)

Watchlist
  • 0.0000
  • 0.00000.00%
Close Dec 20 09:30 ET
0Market Cap0.00P/E (TTM)

About Immuron Limited C/Wts 12/05/2022 (To Pur Com) Company

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Company Profile

SymbolIMRNW
Company NameImmuron Limited C/Wts 12/05/2022 (To Pur Com)
CEODr. Jerry Kanellos, PhD
MarketNASDAQ
Employees5

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jerry Kanellos, PhD
  • Chief Executive Officer and Chief Operating Officer
  • --
  • Phillip A. Hains
  • Chief Financial Officer and Secretary
  • --
  • Dr. Roger Aston
  • Non-Executive Chairman of the Board
  • --
  • Professor Ravi Savarirayan
  • Independent Director
  • --
  • Daniel Pollock
  • Independent Director
  • --
  • Stephen Anastasiou
  • Independent Director
  • --
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.